Spots Global Cancer Trial Database for hodgkin
Every month we try and update this database with for hodgkin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim | NCT04947618 | Lymphoma, Malig... | 15 Years - | Centre Hospitalier Universitaire de Nīmes | ||
| Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients | NCT01613300 | B-Cell Lymphoma... | Ofatumumab | 18 Years - 65 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma | NCT01195766 | Hodgkin Disease | Ofatumumab | 18 Years - 75 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma | NCT01884428 | Hodgkin's Lymph... | panobinostat Ifosfamide Gemcitabine Vinorelbine Prednisolone | 18 Years - 65 Years | Istituto Clinico Humanitas | |
| Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis | NCT03552003 | Classical Hodgk... | Treatment for c... | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis | NCT03552003 | Classical Hodgk... | Treatment for c... | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-Obs | NCT04630275 | Hypogonadism | 18 Years - 65 Years | Herlev Hospital | ||
| Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma | NCT01884428 | Hodgkin's Lymph... | panobinostat Ifosfamide Gemcitabine Vinorelbine Prednisolone | 18 Years - 65 Years | Istituto Clinico Humanitas | |
| Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer | NCT01691040 | Anemia of Chron... | NOX-H94 Placebo solutio... | 18 Years - | TME Pharma AG | |
| Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients | NCT01884441 | Hodgkin's Lymph... | Bendamustine Gemcitabine Vinorelbine | 18 Years - | Istituto Clinico Humanitas | |
| Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma | NCT01492088 | Relapsed or Ref... Relapsed or Ref... | Brentuximab ved... | 2 Years - 18 Years | Takeda | |
| Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma | NCT00722865 | Hodgkin Lymphom... | Avastin | 18 Years - | Massachusetts General Hospital | |
| Proton Radiation for Lymphoma Involving Mediastinum | NCT01751412 | Lymphoma | Proton Radiatio... | 6 Years - | Massachusetts General Hospital | |
| Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-Obs | NCT04630275 | Hypogonadism | 18 Years - 65 Years | Herlev Hospital | ||
| A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma | NCT01950364 | Hodgkin Lymphom... Anaplastic Larg... | brentuximab ved... Brentuximab ved... | 18 Years - 75 Years | Millennium Pharmaceuticals, Inc. | |
| Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-Obs | NCT04630275 | Hypogonadism | 18 Years - 65 Years | Herlev Hospital | ||
| Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer | NCT01691040 | Anemia of Chron... | NOX-H94 Placebo solutio... | 18 Years - | TME Pharma AG | |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | NCT01990534 | Hodgkin Lymphom... | Brentuximab Ved... | 18 Years - | Takeda | |
| Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy | NCT05977673 | Hodgkin Lymphom... | Tislelizumab | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma | NCT00478959 | Hodgkin Disease | Lenalidomide (R... | 18 Years - | University Health Network, Toronto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
